NYSE$HAE
Haemonetics Corp. · Q2 2025 earnings
Q2 2025 earnings · · Investor relations
Briefing
Haemonetics reported strong results driven by portfolio evolution and market trend response.
Haemonetics Corporation reported an 8.6% increase in revenue for the second quarter of fiscal 2025, with significant growth in the Hospital business unit. The company's adjusted earnings per diluted share increased by 13.1% to $1.12. Haemonetics updated its fiscal 2025 revenue guidance and reaffirmed its adjusted operating margin, adjusted earnings per diluted share, and free cash flow guidance.
- Second quarter fiscal 2025 revenue increased by 8.6% to $345.5 million compared to the prior year.
- Adjusted earnings per diluted share for the second quarter of fiscal 2025 increased by 13.1% to $1.12.
- The company reaffirmed its adjusted operating margin guidance, adjusted earnings per diluted share guidance and free cash flow guidance.
- Cash on hand increased by $120.5 million since the end of fiscal 2024, driven by debt financing activities.
Headline financials
Revenue & EPS history
Haemonetics · Revenue · Quarterly
$346M
Revenue by segment
Haemonetics · $313M total across 3 segments · Q2 2024
- Plasma$142M+11.0%45.3%
- Hospital$103M+13.5%32.9%
- Blood Center$68.1M-7.6%21.7%
Forward guidance
The Company updated its fiscal 2025 GAAP total revenue and organic revenue growth guidance and reaffirmed its adjusted operating margin guidance, adjusted earnings per diluted share guidance and free cash flow guidance.
Tailwinds
- Total Company Reported Revenue growth: 5 - 8%
- Hospital growth: 26% - 31%
- Total Company Organic growth: 1 - 4%
- Adjusted operating margin: 23% - 24%
- Adjusted earnings per diluted share: $4.45 - $4.75
Headwinds
- Plasma growth: (3 - 6)%
- Blood Center growth: (4 - 7)%
- Currency impact on total company: (0 - 1)%
- Acquisitions impact on total company: 4 - 5%
- Free cash flow: $130M - $180M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2025
+1.4%
Avg return
Earnings day
+4.1%
Avg return
5 days after
+6.5%
Avg return
30 days after
56%
38 / 68 earnings
Positive
+31.8%
Q2 2026
Best reaction
-15.0%
Q4 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +3.3% | +2.5% | +35.5% | |
| Q3 2026 | -1.4% | -9.8% | -2.8% | |
| Q2 2026 | +31.8% | +41.4% | +65.5% | |
| Q4 2025 | +5.9% | +7.6% | +9.7% | |
| Q3 2025 | -11.6% | -13.6% | -3.6% | |
| Q2 2025 | +11.8% | +19.5% | +3.9% | |
| Q1 2025 | -10.1% | -13.4% | -14.6% | |
| Q4 2024 | +2.8% | +4.4% | -8.2% | |
| Q3 2024 | -3.8% | -7.0% | +3.2% | |
| Q2 2024 | +2.4% | +2.5% | -2.5% | |
| Q1 2024 | +2.0% | +3.0% | -0.8% | |
| Q4 2023 | +7.6% | +7.4% | +6.1% | |
| Q3 2023 | -5.4% | -8.2% | -12.2% | |
| Q2 2023 | +4.1% | -1.7% | +3.5% | |
| Q1 2023 | +8.1% | +12.3% | +13.7% | |
| Q4 2022 | +3.9% | +14.1% | +31.5% | |
| Q3 2022 | +21.2% | +24.5% | +18.9% | |
| Q2 2022 | -13.5% | -15.7% | -24.8% | |
| Q1 2022 | +8.4% | +1.8% | +16.8% | |
| Q4 2021 | -6.4% | -5.4% | +0.4% | |
| Q3 2021 | +12.8% | +21.1% | +4.0% | |
| Q2 2021 | -3.7% | +5.6% | +13.2% | |
| Q1 2021 | -12.7% | -8.5% | +3.3% | |
| Q4 2020 | -8.8% | -3.4% | -11.1% | |
| Q3 2020 | +7.2% | +7.7% | -7.3% | |
| Q2 2020 | +0.3% | +0.5% | -0.1% | |
| Q1 2020 | +10.5% | +13.5% | +10.8% | |
| Q4 2019 | +2.8% | +3.4% | +10.0% | |
| Q3 2019 | -12.2% | -14.3% | -13.0% | |
| Q2 2019 | +9.1% | +5.8% | -0.2% | |
| Q1 2019 | +4.8% | +2.7% | +14.4% | |
| Q4 2018 | +5.8% | +11.2% | +18.9% | |
| Q3 2018 | +14.8% | +13.1% | +20.5% | |
| Q2 2018 | +15.8% | +16.4% | +20.8% | |
| Q1 2018 | +4.2% | +3.2% | +3.9% | |
| Q4 2017 | -1.9% | -4.4% | -4.0% | |
| Q3 2017 | -10.1% | -9.0% | -7.3% | |
| Q2 2017 | +10.5% | +13.8% | +16.5% | |
| Q1 2017 | +13.8% | +16.8% | +22.6% | |
| Q4 2016 | -15.0% | — | — | |
| Q3 2016 | +5.9% | — | — | |
| Q2 2016 | -3.9% | — | — | |
| Q1 2016 | +1.5% | — | — | |
| Q4 2015 | -3.9% | — | — | |
| Q3 2015 | +7.0% | — | — | |
| Q2 2015 | -5.9% | — | — | |
| Q1 2015 | -1.4% | — | — | |
| Q4 2014 | -8.0% | — | — | |
| Q3 2014 | -2.6% | — | — | |
| Q2 2014 | +1.5% | — | — | |
| Q1 2014 | +0.7% | — | — | |
| Q4 2013 | -1.4% | — | — | |
| Q3 2013 | -5.6% | — | — | |
| Q2 2013 | +4.3% | — | — | |
| Q1 2013 | -0.1% | — | — | |
| Q4 2012 | +4.2% | — | — | |
| Q3 2012 | -1.0% | — | — | |
| Q2 2012 | +0.4% | — | — | |
| Q1 2012 | +3.1% | — | — | |
| Q4 2011 | +1.3% | — | — | |
| Q4 2009 | +1.3% | — | — | |
| Q3 2010 | -1.3% | — | — | |
| Q3 2011 | -1.3% | — | — | |
| Q2 2011 | +1.7% | — | — | |
| Q1 2010 | -2.5% | — | — | |
| Q2 2010 | -2.5% | — | — | |
| Q1 2011 | -2.5% | — | — | |
| Q4 2010 | -2.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro